{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:14:21Z","timestamp":1793837661823,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012487","name":"Interdisciplinary Medicine Seed Fund of Peking University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21807006"],"award-info":[{"award-number":["21807006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273772"],"award-info":[{"award-number":["82273772"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["BMU2020MX016"],"award-info":[{"award-number":["BMU2020MX016"]}],"id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ejmech.2023.115343","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T02:11:13Z","timestamp":1680833473000},"page":"115343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells"],"prefix":"10.1016","volume":"254","author":[{"given":"Han","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5249-8950","authenticated-orcid":false,"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cangxin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoquan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangren","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115343_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115343_bib2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of sensitivity and resistance to CDK4\/6 inhibition","volume":"37","author":"Alvarez-Fernandez","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2023.115343_bib3","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1200\/JCO.21.01845","article-title":"Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies","volume":"40","author":"Passaro","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115343_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114009","article-title":"Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib","volume":"229","author":"Ran","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115343_bib5","doi-asserted-by":"crossref","first-page":"10680","DOI":"10.1021\/acs.jmedchem.1c01126","article-title":"The future of medicinal chemistry, PROTAC, and undruggable drug targets","volume":"64","author":"Poso","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115343_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115343_bib7","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115343_bib8","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","article-title":"Selective small molecule induced degradation of the BET bromodomain protein BRD4","volume":"10","author":"Zengerle","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115343_bib9","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC design for the degradation of oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew. Chem.-Int. Edit."},{"key":"10.1016\/j.ejmech.2023.115343_bib10","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","article-title":"Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer","volume":"62","author":"Han","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115343_bib11","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/acs.jmedchem.8b01572","article-title":"Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER)","volume":"62","author":"Hu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115343_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21159-7","article-title":"Mutant-selective degradation by BRAF-targeting PROTACs","volume":"12","author":"Alabi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115343_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2023.115343_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107966","article-title":"Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials","volume":"230","author":"Song","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.115343_bib15","first-page":"1","article-title":"Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115343_bib16","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115343_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","article-title":"CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4","volume":"40","author":"Liao","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2023.115343_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107992","article-title":"Emerging role of ferroptosis in breast cancer: new dawn for overcoming tumor progression","volume":"232","author":"Sui","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.115343_bib19","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2021.12.001","article-title":"Persister cancer cells: iron addiction and vulnerability to ferroptosis","volume":"82","author":"Rodriguez","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2023.115343_bib20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115343_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","article-title":"Ferroptosis: molecular mechanisms and health implications","volume":"31","author":"Tang","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2023.115343_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201800311","article-title":"GPX4 at the crossroads of lipid homeostasis and ferroptosis","volume":"19","author":"Forcina","year":"2019","journal-title":"Proteomics"},{"key":"10.1016\/j.ejmech.2023.115343_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature24297","article-title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115343_bib24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nature23007","article-title":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","volume":"547","author":"Viswanathan","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115343_bib25","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","article-title":"Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer","volume":"81","author":"Ghoochani","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115343_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01016-8","article-title":"Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells","volume":"14","author":"Ding","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2023.115343_bib27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1107\/S2059798320016125","article-title":"Crystal structures of the selenoprotein glutathione peroxidase 4 in its apo form and in complex with the covalently bound inhibitor ML162","volume":"77","author":"Moosmayer","year":"2021","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"10.1016\/j.ejmech.2023.115343_bib28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41589-020-0501-5","article-title":"Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles","volume":"16","author":"Eaton","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115343_bib29","doi-asserted-by":"crossref","first-page":"11788","DOI":"10.1021\/acs.jmedchem.2c00909","article-title":"Tunable cysteine-targeting electrophilic heteroaromatic warheads induce ferroptosis","volume":"65","author":"Karaj","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115343_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41589-021-00915-2","article-title":"Characterization of a patient-derived variant of GPX4 for precision therapy","volume":"18","author":"Liu","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115343_bib31","volume":"CN113336748","author":"Xu","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115343_bib32","article-title":"Dual degradation mechanism of GPX4 degrader in induction of ferroptosis exerting anti-resistant tumor effect","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115343_bib33","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.chembiol.2022.11.003","article-title":"Small-molecule allosteric inhibitors of GPX4","volume":"29","author":"Liu","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115343_bib34","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115343_bib35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ddtec.2019.02.005","article-title":"Targeted protein degradation in vivo with Proteolysis Targeting Chimeras: current status and future considerations","volume":"31","author":"Watt","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejmech.2023.115343_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-03297-w","article-title":"Acid sphingomyelinase-dependent autophagic degradation of GPX4 is critical for the execution of ferroptosis","volume":"12","author":"Thayyullathil","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2023.115343_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112271","article-title":"Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs","volume":"196","author":"Wang","year":"2020","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423003094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423003094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:52:48Z","timestamp":1759330368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423003094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":37,"alternative-id":["S0223523423003094"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115343","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115343"}}